Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising results from a novel BMS androgen receptor antagonist and degrader in heavily pretreated patients. New data also highlighted the risks of treatment interruption in castration-sensitive disease and emphasized the growing role of PARP inhibitors for BRCA1/2-mutated tumors. Dose adjustments of apalutamide were shown to reduce rash without compromising cancer control.
Radiotherapeutics took the spotlight with Actinium-225-PSMA therapy showing effectiveness, including when combined with lutetium-177. Surgical studies like IP2-ATLANTA demonstrated the feasibility of cytoreductive treatments, while PSMA PET-guided metastasis-directed therapy showed potential for improving outcomes in patients with biochemical recurrence.
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD/Medscape or its affiliates.
